Filing Details
- Accession Number:
- 0001209191-21-055867
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-14 16:01:27
- Reporting Period:
- 2021-09-13
- Accepted Time:
- 2021-09-14 16:01:27
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 651311552 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1748177 | Bahram Valamehr | C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131 | Chief Development Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-09-13 | 25,000 | $2.73 | 120,740 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-09-13 | 15,809 | $65.94 | 104,931 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-09-13 | 8,391 | $66.84 | 96,540 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-09-13 | 800 | $67.46 | 95,740 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-09-13 | 25,000 | $0.00 | 25,000 | $2.73 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 86,156 | 2027-01-04 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.
- Represents the weighted average sale price of the shares sold from $65.40 to $66.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4.
- Represents the weighted average sale price of the shares sold from $66.40 to $67.38 per share.
- Represents the weighted average sale price of the shares sold from $67.40 to $67.54 per share.
- This option is fully vested.
Billionaire Hedge Funds
